FDA SANCTIONS THE USE OF VEKLURY UNDER ITS ‘EMERGENCY USE AUTHORIZATION’ FOR TREATMENT OF HOSPITALISED COVID-19 PATIENTS

by Chhavi Madaan | 2020-08-29

On the 28th of August, the United States Food and Drug Administration extended the use of Veklury, commonly known as Remdesivir, for the treatment of all patients hospitalized due to COVID-19.

The Food and Drug Administration had initially certified the use of Remdesivir under its Emergency Use Authorization only in the treatment of patients with severe symptoms and ailments.

Initially, the usage of Veklury was restricted to patients who needed immediate medical assistance, such as in cases of receding blood oxygen level, a complication in breathing, or an additional relief in a ventilator.


What is Veklury or Remdesivir?

Remdesivir is an antiviral drug manufactured by Gilead Sciences under the name Veklury. The medication’s efficiency has maintained a status of anticipation. The drug was initially formulated to treat Hepatitis and was also administered during the Ebola virus crisis with insignificant results. However, research in the field claims that Remdesivir has a notable impact on Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome.

How does Remdesivir Function as a Defense against COVID-19?

Numerous surveys have tested the efficiency of Remdesivir in the past. However, the tests are confined to animal subjects.

The COVID-19 virus upon entering the bloodstream begins manipulating the blood cells to replicate the production of Coronavirus through an enzyme ‘RdRp.’ Remdesivir, once injected, prevents this manipulation by thwarting the production of the RdRp enzyme.

Clinical trials prove that Remdesivir stimulates the process of recovery from COVID-19.

The Experiments Conducted

‘The National Institute of Allergy and Infectious Diseases’ conducted tests on Remdesivir. About 1062 COVID-19 patients were provided either Placebo or Veklury. Results revealed that the recovery in Remdesivir patients was ten days, five days less than the Placebo patients.

Administration of Remdesivir in Coronavirus patients showed a 31% rise in recovery rate. Studies also state that Remdesivir reduces the mortality rate in Coronavirus patients. The earlier the patient is provided with Remdesivir, the higher is its efficiency.

As a response to the growing atrocities of the COVID-19 Pandemic and the absence of a vaccine, the Food and Drug Administration revised its Emergency Use Authorization of Remdesivir.

The decision was made to contain Coronavirus’s spread, provide relief to patients, and shorten the recovery phase.

However, Remdesivir comes with a set of side-effects, one being crucial liver damage. Some Scientists and Researchers even question the impact of Remdesivir in the treatment if COVID-19. Considering the lack of research on Veklury, the United States Food and Drug Administration has only issued an Emergency Use Authorization that can be legally altered.

Stay Safe. Stay Healthy. Stay Tuned.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *